Andra AP fonden Acquires New Position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

Andra AP fonden acquired a new stake in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) in the first quarter, HoldingsChannel reports. The fund acquired 14,600 shares of the biopharmaceutical company’s stock, valued at approximately $5,995,000.

Other hedge funds have also recently bought and sold shares of the company. BlackRock Inc. increased its holdings in Regeneron Pharmaceuticals by 1.9% in the first quarter. BlackRock Inc. now owns 6,042,908 shares of the biopharmaceutical company’s stock worth $2,481,339,000 after buying an additional 113,683 shares during the last quarter. Vanguard Group Inc increased its holdings in Regeneron Pharmaceuticals by 1.3% in the third quarter. Vanguard Group Inc now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after buying an additional 75,868 shares during the last quarter. FMR LLC increased its holdings in Regeneron Pharmaceuticals by 6.6% in the fourth quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock worth $1,997,245,000 after buying an additional 330,875 shares during the last quarter. Geode Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock worth $402,138,000 after buying an additional 78,143 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in Regeneron Pharmaceuticals by 16.6% in the fourth quarter. American Century Companies Inc. now owns 1,003,471 shares of the biopharmaceutical company’s stock worth $374,796,000 after buying an additional 142,779 shares during the last quarter. 66.96% of the stock is owned by institutional investors.

In other news, EVP Neil Stahl sold 9,853 shares of the stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $305.74, for a total value of $3,012,456.22. Following the completion of the sale, the executive vice president now directly owns 47,450 shares of the company’s stock, valued at $14,507,363. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total value of $305,930.00. Following the completion of the sale, the director now directly owns 11,323 shares of the company’s stock, valued at $3,464,045.39. The disclosure for this sale can be found here. 11.84% of the stock is currently owned by corporate insiders.

Shares of Regeneron Pharmaceuticals stock opened at $305.24 on Friday. Regeneron Pharmaceuticals Inc has a 12-month low of $295.27 and a 12-month high of $442.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.58 and a quick ratio of 3.78. The company has a market cap of $33.36 billion, a price-to-earnings ratio of 15.42, a P/E/G ratio of 1.44 and a beta of 1.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share for the quarter, missing the consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.76 billion. During the same period in the prior year, the company posted $4.67 earnings per share. The firm’s revenue was up 13.3% compared to the same quarter last year. As a group, equities analysts predict that Regeneron Pharmaceuticals Inc will post 18.37 EPS for the current fiscal year.

REGN has been the subject of a number of recent analyst reports. Guggenheim cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $466.00 to $425.00 in a research report on Friday, February 22nd. BidaskClub raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $435.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 7th. ValuEngine raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, May 23rd. Finally, Cowen reaffirmed a “hold” rating and set a $353.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday, May 7th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Hold” and a consensus target price of $395.78.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2019/06/15/andra-ap-fonden-acquires-new-position-in-regeneron-pharmaceuticals-inc-nasdaqregn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Story: Stock Symbol

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.